DNA Script, Moderna Team Up For On-Demand Vaccines and Therapeutics For DARPA

DNA Script today announced a partnership with Moderna Inc (NASDAQ: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program.
The partnership will employ DNA Script's novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids without using hazardous chemical solvents to power Moderna's existing manufacturing technology for the rapid production of messenger RNA therapeutics and vaccines.
As part of the agreement, DNA Script will receive up to $5 million in grant funding from DARPA.
Price Action: MRNA shares are up 2.86% at $182.72 in the market trading session on the last check Tuesday.